Wednesday, April 15 at 8 am Pacific

Register here

Join host John Cumbers for the latest developments from the synthetic biology industry, and these in-depth conversations:

As biotech founders attempt to inoculate their teams against the economic and social upheaval of SARS-CoV-2, what is the investment community doing? As the world turns attention toward biotech companies to solve this pandemic, does the synthetic biology industry represent an even richer opportunity? Or will the funding frenzy cool off? SynBioBeta founder John Cumbers talks with four investors at the forefront of synthetic biology:

The brain is central to our humanity, but when problems arise, we dont have good tools to work with it. Brain-computer interfaces represent a new class of digital therapeutics, allowing access to the brain in areas like sensory and motor prosthetics, monitoring neuropsychiatric conditions, and smart pharmaceutical delivery. Join SynBioBeta founder John Cumbers for a conversation with Matt Angle, CEO of Paradromics, who will share his companys technology for helping as many as 10 million paralysis patients in the US alone. Well be joined by Dr. Loretta Bruening of the Inner Mammal Institute, who will describe the neurochemical basis for happiness, and how each of us can more efficiently interact with our deeper mammalian brain to guide our neurochemistry toward more pleasurable states. We will also be joined by Mark Bunger, Lab Agent at Innovation Labs, who will discuss the neurotech entrepreneurial ecosystem and provide context for the interplay of neurotech, synthetic biology, and other deep tech fields.

Register here:

See original here:
SynBioBeta Live: Investing in times of turmoil, neurotech and happiness - SynBioBeta